For human toxicity, cancer and non-cancer health impacts are considered separately as indicators of disability in USEtox versions 1 and 2. Non-cancer effects are furthermore differentiated into reproductive/developmental toxicity and general non-cancer toxiity as from USEtox version 3 (see Fantke et al. 2021, based on underlying points of departure developed in Aurisano et al. 2023 for oral expsoure and Aurisano et al. 2024 for inhalation exposure). Since all underlying available test data per chemical should be used to derive USEtox effect factors from the lowest converted human lifetime dose per exposure route, all underlying effects are considered in USEtox.
